<DOC>
	<DOC>NCT02011945</DOC>
	<brief_summary>The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.</brief_summary>
	<brief_title>A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Confirmed diagnosis of Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase : With historically documented Ph+ cells â‰¥2 prior Tyrosine Kinase Inhibitors (TKI) therapies for CML Currently progressing, resistance to or with a suboptimal response to their most recent therapy Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score 0 1 Blast phase CML Known Ablkinase mutation resistant to Dasatinib (e.g. T315I or T315A)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>